Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

3.7K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
3.7K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

2.9K
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
2.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment of Progressive Multifocal Leukoencephalopathy with Third-Party Allogeneic BK Virus T Cells.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Advancing CAR-NK cell therapy in solid tumors: Current landscape and future directions.

Cell reports. Medicine·2026
Same author

Outsmarting NK surveillance: engineering stealth CAR T cells.

Blood advances·2026
Same author

Long-term follow-up: blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia.

Haematologica·2026
Same author

Late Cytomegalovirus Infections After Allogeneic Hematopoietic Cell Transplant.

American journal of hematology·2026
Same author

Cultural Adaptation and Feasibility of an Inpatient Yoga Intervention for Patients Undergoing Hematopoietic Stem Cell Transplantation in Tanzania, India, and the United States: A Study Protocol.

Global advances in integrative medicine and health·2026

Related Experiment Video

Updated: Apr 24, 2026

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

1.9K

CAR-NK cell therapy for hematological malignancies.

Gohar Shahwar Manzar1, Md Faqrul Hasan1, Madison Moore2,3

  • 1Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.

Blood Advances
|April 22, 2026
PubMed
Summary

Chimeric antigen receptor (CAR)-natural killer (NK) cells offer a safer, scalable cell therapy for blood cancers. Innovations are overcoming challenges like persistence and exhaustion for enhanced efficacy.

More Related Videos

Natural Killer NK and CAR-NK Cell Expansion Method using Membrane Bound-IL-21-Modified B Cell Line
11:02

Natural Killer NK and CAR-NK Cell Expansion Method using Membrane Bound-IL-21-Modified B Cell Line

Published on: February 8, 2022

9.3K
Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy
07:33

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Published on: September 19, 2025

997

Related Experiment Videos

Last Updated: Apr 24, 2026

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

1.9K
Natural Killer NK and CAR-NK Cell Expansion Method using Membrane Bound-IL-21-Modified B Cell Line
11:02

Natural Killer NK and CAR-NK Cell Expansion Method using Membrane Bound-IL-21-Modified B Cell Line

Published on: February 8, 2022

9.3K
Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy
07:33

Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy

Published on: September 19, 2025

997

Area of Science:

  • Immunology
  • Cell Therapy
  • Oncology

Background:

  • Chimeric antigen receptor (CAR)-natural killer (NK) cells are an emerging cell therapy.
  • They offer advantages over CAR-T cells, including improved safety, scalability, and innate cytotoxicity.
  • CAR-NK cells have shown promise in treating hematologic malignancies.

Purpose of the Study:

  • To review current trends and innovations in CAR-NK cell engineering.
  • To examine biological and technical challenges in CAR-NK cell therapy.
  • To outline preclinical approaches and early-phase clinical trials.

Main Methods:

  • Literature review of current trends in CAR-NK cell engineering.
  • Analysis of challenges in CAR-NK cell therapy, including in vivo persistence, metabolic issues, and immunosuppression.
  • Summary of preclinical strategies and ongoing clinical trials.

Main Results:

  • CAR-NK cells demonstrate a favorable safety profile and therapeutic efficacy in hematologic malignancies.
  • Challenges such as NK cell persistence, metabolic limitations, and tumor-induced exhaustion are being addressed.
  • Innovations in CAR-NK engineering are paving the way for improved treatments.

Conclusions:

  • CAR-NK cell therapy holds transformative potential for hematological cancers.
  • Ongoing research and clinical trials are focused on overcoming existing limitations.
  • The field is rapidly advancing, promising new therapeutic options.